20 January 2021 | News
In accordance with the strategic agreement, Jianshun will provide Etta Biotech with customised cell culture media for its transient protein expression platform
Source credit: businesswire
Jianshun Biosciences Co Ltd has announced its strategic partnership with Etta Biotech Co Ltd, in China to set up a high titer transient protein expression platform for high quality protein production using Jianshun’s transient transfection media. Jianshun becomes the exclusive cell culture supplier for Etta Biotech’s transient transfection high titer protein expression platform.
Etta Biotech is a leading cell electroporation technology and equipment supplier. Its proprietary large-capacity flow electroporator, X-Porator F1, is one of the only two products of its kind in the world, and leads the market with its outstanding performance and customer value.
In accordance with the strategic agreement, Jianshun will provide Etta Biotech with customised cell culture media for its transient protein expression platform. The two parties also plan to join force further to build a rapid protein production platform aiming at producing gram-scale protein for R&D, eg molecular assessment within two weeks after receiving plasmids, to advance R&D process for antibody drug development.
Dr Edward Dai, Chairman and CEO, Etta Biotech, said: “I am so glad to have the opportunity to join hands with the benchmark company in cell culture media, JS Bio. Its cell culture media specially developed for Etta Biotech’s electroporator can further increase our customers’ protein output, and guarantee a supply of reliable cell culture medium products for Etta Biotech’s high titer protein transient expression platform.”
Dr Shun Luo, Chairman and President at JS Bio, commented: “Presently, we and Etta Biotech have achieved great progresses in developing transient transfection platforms with high protein expression titer, and protein production systems at scale.